Trial Profile
A Randomized, Double-Blind, Outpatient, Placebo-Controlled, Dose Titration Study Of Gastrointestinal Tolerability Of Pf 05212389 (Oap-189) In Obese Subjects.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2011
Price :
$35
*
At a glance
- Drugs OAP 189 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Nov 2011 New trial record